LQT5

LQT5 refers to a rare genetic variant of long QT syndrome (LQTS), a condition characterized by prolonged QT interval on an electrocardiogram (ECG) and an increased risk of potentially fatal arrhythmias, such as torsades de pointes. Unlike the more commonly recognized forms of LQTS (LQT1, LQT2, and LQT3), LQT5 is associated with mutations in the KCNJ2 gene, which encodes the inward rectifier potassium channel Kir2.1.

The KCNJ2 gene plays a critical role in regulating cardiac repolarization, the process by which the heart muscle recovers from a heartbeat. Mutations in this gene disrupt normal potassium flow, leading to abnormal electrical activity in the heart. This imbalance can cause the QT interval—the time between the start of the Q wave and the end of the T wave on an ECG—to lengthen, increasing the risk of arrhythmias.

Symptoms of LQT5 are similar to those of other LQT subtypes, including syncope (fainting), seizures, and sudden cardiac arrest. The condition is typically diagnosed through genetic testing, ECG analysis, and family history assessment. Treatment often involves lifestyle modifications, such as avoiding triggers like stress, intense exercise, and certain medications that can prolong the QT interval. Beta-blockers are commonly prescribed to reduce arrhythmia risk, though other antiarrhythmic drugs may be considered in some cases.

LQT5 is inherited in an autosomal dominant pattern, meaning an affected individual has a 50% chance of passing the mutation to each of their children. Early diagnosis and management are essential for improving long-term outcomes, as timely intervention can significantly reduce the risk of life-threatening complications. Research into LQT5 remains ongoing, with ongoing efforts to better understand its mechanisms and develop more targeted therapies.